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Abstract
Objective
To determine the case-fatality rate (CFR) at the end of the intensive phase of tuberculosis
(TB) treatment, and factors associated with fatality.
Methods
TB patients diagnosed between 2006 and 2013 were followed-up during treatment. We
computed the CFR at the end of the intensive phase of TB treatment, and the incidence of
death per 100 person-days (pd) of follow-up. We performed survival analysis using the
Kaplan-Meier method and Cox regression, and calculate hazard ratios (HR) and 95% confi-
dence intervals (CI).
Results
A total of 5,182 patients were included, of whom 180 (3.5%) died; 87 of these deaths
(48.3%) occurred during the intensive phase of treatment, with a CFR of 1.7%. The inci-
dence of death was 0.028/100 pd. The following factors were associated with death during
the intensive phase: being >50 years (HR = 36.9;CI:4.8–283.4); being retired (HR = 2.4;
CI:1.1–5.1); having visited the emergency department (HR = 3.1;CI:1.2–7.7); HIV infection
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(HR = 3.4;CI:1.6–7.2); initial standard treatment with 3 drugs (HR = 2.0;CI:1.2–3.3) or non-
standard treatments (HR = 2.68;CI:1.36–5.25); comprehension difficulties (HR = 2.8;
CI:1.3–6.1); and smear-positive sputum (HR = 2.3-CI:1.0–4.8).
Conclusion
There is a non-negligible CFR during the intensive phase of TB, whose reduction should be
prioritised. The CFR could be a useful indicator for evaluating TB programs.
Introduction
Tuberculosis (TB) is a curable disease and is considered to be a cause of unnecessarily prema-
ture and avoidable deaths [1] that should be eradicated as a cause of death [2]. While global TB
mortality is estimated to have decreased by 45% between 1990 and 2013, it was still the cause of
1.5 million deaths in 2014, more than the number caused by HIV (1.2 million) [3]. Moreover,
studies show that the death rate among TB cases is underestimated [4], and TB is often not the
cause of death but rather a contributing factor [2]. Furthermore, mortality among TB patients
varies considerably between countries. In Europe it was ~7% in 2012 [5], varying from 12% in
Slovakia to 5% in The Netherlands [6] and United Kingdom [7]. Other studies indicate mortal-
ity of 6.6% in the United States and Canada [8], 5.5% in Shangai [9], 12% in Rwanda [10], 18%
in the Chiapas region of Mexico [11], 19.7% in Taiwan [12], and 26.6% in Pakistan [13]. There
is little data on mortality and survival among TB patients, and a recently European study on
the topic [6] indicated that no information was available for Spain.
It is widely known that an important percentage of deaths among TB patients occur during
the early phases of anti-TB therapy. However, to date few studies have investigated the case
fatality rate (CFR) during the intensive phase of treatment [14–15]. The identification of the
characteristics of patients who die prematurely during Tb treatment could help identify vulner-
able populations and help to target them in future public health interventions. Thus, the main
objective of the present study was to determine the CFR and its associated factors during the
intensive phase of TB treatment in a large cohort of patients.
Materials and Methods
Design: A population-based prospective cohort study.
Study subjects: Patients diagnosed with TB between 1 January 2006 and 31 December 2013
in one of 61 Spanish hospitals by a member of the Working Group of Integrated Programme of
Tuberculosis Research.
Identification and follow-up of cases
Inclusion criteria: 1) Positive smear-test, or negative but with culture positive forMycobacte-
rium tuberculosis; or, in cases of extrapulmonary TB, demonstration of caseating granulomas
in histology. 2) Patients with suspected TB (based on clinical, radiological, epidemiological or
laboratory results). 3) Age>18 years old; 4) Informed consent given.
Cases were followed up according to the assessment schedule provided in Table 1. The
cause of death was decided and documented by the managing physician.
All data were via a standardized online questionnaire, and were stored in an electronic case
report; only the doctor in charge of the patient had access to the patient’s data, via a username
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and password specified for each collaborating study investigator. We created a database, which
was the responsibility of our project manager.
Variables
The variables studied were: sex; age; country of origin; employment status; living arrangements;
comprehension difficulties; health center that made the diagnosis and followed up the case; his-
tory of consumption of tobacco, alcohol and injected drugs; HIV infection; previous TB treat-
ment; TB localisation; microbiology; Chest-X-Ray; drug resistance; treatment regime; initial
and final dates of intensive treatment phase; date of end of treatment; treatment outcome
(cured, treatment completed, therapeutic failure, moved away/transferred, lost to follow-up,
prolongation of TB treatment, and death due to TB or other cause with date of death).
Statistical Analysis
We carried out a descriptive study of qualitative and quantitative variables to characterize the
study population. We computed the frequency distributions of the qualitative variables, and
compared proportions using the χ2 test, or the two-tailed Fisher test when expected values
were>5.
We computed the incidence of death during the intensive phase of TB treatment per 100
person-days (pd) of follow-up. The duration of follow-up was defined as the interval from the
date when treatment began until the end of the intensive phase of anti-tuberculosis treatment
(2 months). The CFR was calculated as the percentage of deaths during the intensive phase
among patients who started treatment.
In the bivariate analysis, the probability of death was determined using the Kaplan-Meier
method, and survival curves were compared using the Log-Rank test. We fit bivariate and mul-
tivariate Cox proportional hazards models. We used the backward stepwisemethod of selection
for the Cox multivariate model, including associated factors (p<0.05) from the bivariate level.
All variables without collinearity were included in the final model and interaction between
covariates was assessed.
We calculated measures of association (hazard ratios, HR) and their 95% confidence inter-
vals (CI), and considered p-values<0.05 as statistically significant. Proportionality of hazards
Table 1. Evaluation schedule of cases diagnosed of tuberculosis.
Visit 1 Visit 2 Visit 3 Visit 4
Diagnosis 2 Months 6 Months 9,12,18 Months (Optional)
Inclusion/Exclusion criteria x
Socio-demographic data x
Smoking/alcohol habits x
Anthropometrics x x x x
Clinical history x
Diagnostic methods x
Drug treatment x x x x
Clinical response x x x
Treatment adherence x x x
Sputum sample collection x x x x
Drug susceptibility testing x
Treatment outcome x x
doi:10.1371/journal.pone.0159925.t001
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was assessed using Schoenfeld residuals. All analyses were conducted using version 3.1.1 of the
R statistical package.
Ethical aspects
In accordance with the International Directory for Ethical Revision of Epidemiological Studies
(Council for the International Organizations of Medical Sciences—CIOMS, Geneva, 1991),
and the Spanish Epidemiology Society recommendations on ethical aspects of epidemiological
research, this study was approved by the Teknon Institutional Review Board (IRB). This insti-
tution acted as the reference IRB for all participant centers during 2011, when the grant was
requested. According to Spanish law (Orden SAS/3740/2009), this type of study only requires
the approval of a reference IRB, and were contacted prior to data collection.
All participants gave written informed consent for their clinical records to be used in this
study. All records with patient identification information were handled in a confidential man-
ner according to the ethical principles of the Helsinki Declaration and in accordance with the
Data Protection Spanish Law 15/1999.
Results
A total of 5,182 TB cases were studied. Their median age was 39 years, 62% were males, 31.6%
were foreign-born, 4.2% were HIV-infected, 49.4% were attended at hospital emergency
departments, 77.4% had pulmonary TB, 32.8% presented X-ray cavitation, 6.9% were resistant
at least to one drug, and 6.7% had difficulty understanding the disease and/or the treatment
(Table 2).
A total of 180 patients (3.5%) died during TB treatment, 87 (48.3%) during the intensive
phase. Of these deaths, 34 (39.1%) were atributted to TB.
The incidence of death during the intensive phase was 0.028/100 pd. The CFR during the
initial phase was 1.7% (0.7% due to TB) and the cumulative probabilities of dying at 15, 30, 45
and 60 days were 0.8%, 1.2%, 1.4% and 1.7%, respectively (Fig 1). The intensive phase CFR dur-
ing the study period as follows: 0.8%, 1.8%, 2.1%, 1.1%, 1.9%, 2.7%, 2.1% and 1.8% in 2006 to
2013, respectively. Dividing the study into two periods, 2006–2009 and 2010–2013, the CFR
was higher during the second period (1.3% vs 2.2%; p = 0.009).
CFRs for various categories of the variables are shown in Table 2. The bivariate analysis
showed higher mortality among men, people aged 30–50, those born in Spain, retired peo-
ple, the unemployed, individuals diagnosed in hospital emergency departments or health cen-
ters that were not specialist in this area, alcoholics, injecting drug users, individuals infected
with HIV, those with bacteriological confirmation, those who were initially treated with 3
drugs or other non-standard forms of treatment, patients with comprehension difficulties, and
cases diagnosed during the period 2010–2013 (Table 2).
The Kaplan-Meier curves for the main factors that significantly affected probability of death
during the intensive phase of TB treatment are shown in Fig 2.
The multivariate analysis showed that the following factors were associated with a higher
probability of death during the intensive phase of TB treatment: being aged 31–50 or>50
years; being retired; having been attended at the emergency department; being HIV-infected;
being sputum smear-positive; having received initial standard treatment with 3 drugs or with
non-standard therapies, and having comprehension difficulties (Table 2).
Discussion
In this study, which was conducted in a high income country, we observed a non-negligible
CFR during the first two months of TB treatment, and that this was associated with factors
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Table 2. Characteristics of 5,182 patients with tuberculosis, and factors related with the probability of death during the intensive treatment phase.
Bivariate and multivariate analysis.
Total (%) Deaths (%) Bivariate analysis p-value Multivariate analysis p- value
N = 5182 N = 87 (1.7) HR (95% CI) HR (95% CI)
Sex:
Female 1863 (35.9) 19 (1.0) Ref. Ref.
Male 3208 (62.0) 66 (2.1) 2.03 [1.22;3.38] 0.007
NC 111 (2.1) 2 (1.8) 1.78 [0.42;7.65] 0.437
Age:
18–30 1439 (27.8) 1 (0.1) Ref. Ref. Ref. Ref.
31–50 2103(40.6)) 16 (0.8) 11.0 [1.46;82.8] 0.020 8.96 [1.18;67.99] 0.033
>50 1525 (29.4) 70 (4.6) 67.4 [9.37;485.0] <0.001 36.92[4.81;283.39] <0.001
Unknown 115 (2.2) 0 (0) 0.00 [0.00;inf] 0.995 0.00 [0.00;inf] 0.995
Country of origin:
Other 1637 (31.6) 8 (0.5) Ref. Ref.
Spain 3545 (68.4) 79 (2.2) 4.59 [2.22;9.50] <0.001
Employment status:
Active 2750 (53.0) 11 (0.4) Ref. Ref. Ref. Ref.
Retired 885 (17.1) 55 (6.2) 16.0 [8.37;30.5] <0.001 2.40 [1.11;5.14] 0.024
Unemployed 1247 (24.1) 15 (1.2) 3.03 [1.39;6.59] 0.005 1.99 [0.88;4.50] 0.097
Unable to work 107 (2.1) 1 (0.9) 2.33 [0.30;18.0] 0.418 0.70 [0.09;5.61] 0.744
Unknown 193 (3.7) 5 (2.6) 6.59 [2.29;19.0] <0.001 0.97 [0.31;3.00] 0.970
Living arrangements:
Group 555 (10.8) 2 (0.4) Ref. Ref.
Alone 477 (9.2) 12 (2.5) 7.03 [1.57;31.4] 0.011
Homeless 75 (1.4) 4 (5.3) 15.1 [2.77;82.5] 0.002
Conﬁned 63 (1.2) 2 (3.2) 8.93 [1.26;63.4] 0.029
Family 3877 (74.8) 63 (1.6) 4.52 [1.11;18.5] 0.036
Unknown 135 (2.6) 4 (3.0) 8.40 [1.54;45.9] 0.014
Where care received:
Primary care 970 (18.7) 5 (0.5) Ref. Ref. Ref. Ref.
Host. emergency dept. 2558 (49.4) 56 (2.2) 4.27 [1.71;10.7] 0.002 3.06 [1.21;7.70] 0.017
Area specialist 797 (15.4) 11 (1.4) 2.68 [0.93;7.72] 0.067 2.35 [0.80;6.86] 0.117
Other 857 (16.5) 15 (1.8) 3.41 [1.24;9.37] 0.018 1.72 [0.61;4.82] 0.296
Smoking:
Non-smoker 2494 (48.1) 36 (1.4) Ref. Ref.
Smoker 2640 (50.9) 47 (1.8) 1.24 [0.80;1.91] 0.340
Unknown 48 (0.9) 4 (8.3) 5.93 [2.11;16.7] <0.001
Alcohol:
No 3937 (76.0) 55 (1.4) Ref. Ref. Ref. Ref.
Yes 1245 (24.0) 32 (2.6) 1.85 [1.20;2.86] 0.006 1.29 [0.79;2.10] 0.298
Injecting drug user:
No 5120 (98.8) 83(1.6) Ref. Ref.
Yes 62 (1.2) 4 (6.5) 4.08 [1.50;11.1] 0.006
HIV:
No 4034 (77.8) 55 (1.4) Ref. Ref. Ref. Ref.
Yes 219 (4.2) 10 (4.6) 3.38 [1.73;6.64] <0.001 3.36 [1.85;7.17] 0.001
Unknown 929 (17.9) 22 (2.4) 1.75 [1.06;2.86] 0.027 1.21 [0.73;2.02] 0.452
Prior TB treatment
(Continued)
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such as age, being retired, receiving emergency care, HIV-infection, smear positivity, initial
treatment with 3 drugs, non-standard therapies, and having comprehension difficulties.
While the percentage of deaths overall is lower than that observed in other European coun-
tries [5], nearly half of these deaths occured during the intensive phase of TB treatment. More-
over, 39% of deaths during this phase were caused by TB. The observed probability of death by
the end of the intensive phase of TB treatment (1.7%) was lower than that reported for a study
carried out in India: 2% [14], (2.6% [15] among patients treated using directly observed ther-
apy, DOT).
Regarding factors associated with death during the intensive phase of TB treatment, the
influence of age in this study was consistent with previous reports [15], with a much higher HR
in individuals over 50 years of age. This may be due to comorbidities and the natural decline in
immunity after age 60 years [16].
Cases diagnosed in hospital emergency departments (that are referred to a TB centre and
are hospitalized for starts treatment or starts treatment at home under the control of TB area
Table 2. (Continued)
Total (%) Deaths (%) Bivariate analysis p-value Multivariate analysis p- value
N = 5182 N = 87 (1.7) HR (95% CI) HR (95% CI)
Yes 375 (7.2) 5 (1.3) Ref. Ref.
No 4807 (92.8) 82 (1.7) 1.28 [0.52;3.17] 0.588
Localization:
Pulmonary 4009 (77.4) 64 (1.6) Ref. Ref.
Extrapulmonary 487 (9.4) 10 (2.1) 1.29 [0.66;2.52] 0.447
Unknown 686 (13.2) 13 (1.9) 1.19 [0.66;2.16] 0.567
Microbiology:
Culture(-) 922 (17.8) 8(0.9) Ref. Ref.
Smear (+) 2792 (53.9) 51 (1.8) 2.12 [1.00;4.46] 0.049 2.32 [1.04;4.76] 0.038
Smear(-) / Culture (+) 1468 (28.3) 28 (1.9) 2.21 [1.01;4.84] 0.048 1.40 [0.63;3.12] 0.401
Chest X-ray:
Normal 537 (10.4) 7 (1.3) Ref. Ref.
Abnormal, cavitation 1700 (32.8) 28 (1.6) 1.27 [0.55;2.90] 0.576
Abnormal, no cavitation 2785 (53.7) 49 (1.8) 1.35 [0.61;2.98] 0.457
Unknown 160 (3.1) 3 (1.9) 1.45 [0.37;5.59] 0.592
Drug resistence:
No 4826 (93.1) 79 (1.6) Ref. Ref.
Yes 356 (6.9) 8 (2.2) 1.38 [0.66;2.85] 0.390
Initial treatment:
4 drugs 2467 (47.6) 23 (0.9) Ref. Ref. Ref. Ref.
3 drugs 2416 (46.6) 48 (2.0) 2.15 [1.31;3.53] 0.003 1.96 [1.17;3.30] 0.010
Other 299 (5.8) 16 (5.4) 5.91 [3.12;11.2] <0.001 2.68 [1.36;5.25] 0.004
Patient comprehension:
Easy 4665 (90.0) 29 (0.6) Ref. Ref. Ref. Ref.
Difﬁcult 346 (6.7) 8 (2.3) 3.76 [1.72;8.22] 0.001 2.76 [1.25;6.08] 0.011
Unknown 171 (3.3) 50 (29.2) 59.4 [37.6;93.9] <0.001 38.34[23.49;62.5] <0.001
Distribution by period:
2006–2009 3034 (58.5) 39 (1.3) Ref. Ref.
2010–2013 2148 (41.5) 48 (2.2) 1.76 [1.15;2.68] 0.009
HR: Hazard ratio; CI: Conﬁdence interval; Host. emergency dept.: Hospital emergency department; HIV: Human immunodeﬁciency virus; TB: tuberculosis
doi:10.1371/journal.pone.0159925.t002
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specialist) could be clinically more severe, often involving patients with few resources who
contacting health services long after symptoms appear, leading to diagnostic delay and poor
evolution. In addition, the higher mortality among smear-positive patients is logical since this
represents more advanced forms of TB.
Some studies show that a higher CFR and poorer survival in TB patients occurs in more vul-
nerable population groups, such as injecting drug users, those living in poorer areas [17], those
requiring intensive care [18], people with HIV infection [19], resistance to anti-TB drugs [20],
a high degree of lung destruction, [21] and individuals who make inappropriate use of health
services [22]. In our study however, HIV infection is the only factor associated with early
death, despite the fact that mortality has fallen significantly in this group with the use of highly
active antiretroviral therapy (HAART) [23].
Early death among patients treated with 3 drugs may be because of inappropriate treatment
in patients with undetected drug sensitivity or resistance. In Spain the prevalence of resistances
is low [24] and no diferences were observed in our study by resistances (Table 2), however the
people under 3 drugs treatment had a worse survival in relation to people under 4 drugs treat-
ment (HR = 1.96; 95% CI: 1.17–3.30). This is consistent with a study that highlighted inappro-
priate therapy during the intensive treatment phase as a risk factor for death [25]. Moreover,
cases treated with non-standard therapies are generally patients with more complex and more
severe disease (drug resistance, toxicity, intolerance, interactions or therapeutic failures).
Difficulty in comprehending the treatment regime and adherence is widely known to con-
tribute to poor evolution and higher CFR [15]. Our study shows that this is also an indepen-
dent risk factor for early death, and that the death of patients with comprehension difficulties
is more likely to be due to TB than to other causes (75% vs 25%; p<0.001).
Note that mortality may be reduced more rapidly than incidence since early TB treatment
would reduce both transmission and the number of deaths [26]. Thus, it would be interesting to
identify modifiable risk factors associated with death, with the aim of improving clinical out-
comes. One of the goals of theWHO Stop TB strategy is to reduce TB mortality [27], and DOT
has been shown to be the principal action required to achieve this goal [28–30]. Other measures
can also reduce this risk, such as: exhaustive follow-up of older patients [21]; HIV control [31];
early diagnosis, rapid diagnostic techniques [32]; implementation of therapies that prevent and
Fig 1. Probability of dying during the intensive treatment phase in a cohort of 5,182 tuberculosis
patients.
doi:10.1371/journal.pone.0159925.g001
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Fig 2. Probability of death in terms of the main factors that influencemortality during the initial treatment phase.
doi:10.1371/journal.pone.0159925.g002
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control resistance, multidrug-resistant and extensively drug resistant TB [33,34]; and strategies
that improve understanding of therapy and adherence.
The main limitation of this study is the missing data for some patients’ dates of death,
which is necessary for survival analyses; however, the rate of missingness was minimal and did
not affect the study’s objective because these patients died in the maintenance phase of therapy.
Other limitations of this study could be the no inclussion of diagnosis delay (very difficult to
objectivate) and other comorbidities not included in our report form. While it was not possible
to evaluate CD4 count as a factor related to probability of dying, HIV patients with TB have
access to HAART.
The strengths of this study include the large sample size and the fact that the literature
review identified very few publications that studied mortality during the intensive phase of
treatment.
Conclusions
The CRF during the intensive phase of TB treatment phase is non-negligible, as almost half the
deaths occurred during this initial phase of treatment. This CFR could be a good indicator for
evaluating TB programs because it is available early: 2 months after starting treatment. This
would allow program managers to identify a variety of factors in which to intervene (e.g. diag-
nostic delay, inappropriate treatment, resistance, HIV infection), thereby improving survival
among TB patients.
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